A new study challenges a 60-year-old assumption about the body’s main structural building block, opening new possibilities for treating fibrosis and cancer.
Category: biotech/medical – Page 85
Can We Re-grow You?
For all of medical history, we’ve tried to persuade sick cells to behave better. What if instead we just swapped them out? Can we insert new brain cells grown from your own skin cells? And what does any of this have to do with sending one’s own cells into space, or rescuing animals on the very brink of extinction? Today Eagleman talks with stem cell biologist Jeanne Loring about the exciting next horizons.
Subscribe for new episodes every week. 🛎
INNER COSMOS PODCAST: Stanford neuroscientist David Eagleman tackles wild questions that illuminate new facets of our lives.
❤️ iHeartRadio: ihr.fm/3TxDAqb.
🍎 Apple podcasts: apple.co/3LTxTkH
📢 Amazon Music: amzn.to/3ZxGM6R
🟢 Spotify: spoti.fi/3lOaXZl.
X.com/davideagleman.
instagram.com/davideagleman.
fb.com/david.m.eagleman.
linkedin.com/in/davideagleman.
#Eagleman #InnerCosmos #Science #Neuroscience
FEBS Press
A helpful review on immunological responses to adenoviral vectors, a widely used delivery system for gene therapies, anti-tumor therapies, and vaccines.
Adenovirus (AdV) is one of the most widely used vectors for gene therapy and vaccine studies due to its excellent transduction efficiency, capacity for large transgenes, and high levels of gene expression. When administered intravascularly, the fate of AdV vectors is heavily influenced by interactions with host plasma proteins. Some plasma proteins can neutralize AdV, but AdV can also specifically bind plasma proteins that protect against neutralization and preserve activity. This review summarizes the plasma proteins that interact with AdV, including antibodies, complement, and vitamin K-dependent coagulation factors. We will also review the complex interactions of these plasma proteins with each other and with cellular proteins, as well as strategies for developing better AdV vectors that evade or manipulate plasma proteins.
A blood protein can flag dementia risk decades before symptoms appear
Forgetting the name of a loved one may be one of the first signs people notice of dementia, but it’s rarely the first warning sign your brain gives. Changes in the brain that lead to neurodegenerative diseases like Alzheimer’s and dementia start showing up decades before symptoms arrive, and the chemicals at work inside the body can often tip us off to these changes well ahead of time.
A recent study found that a blood protein called GDF15, which is released when cells are under stress, could serve as one of the earliest warning signs of dementia. After tracking more than half a million people for 15–25 years, researchers discovered that those with higher GDF15 levels before age 55 were significantly more likely to develop dementia later in life. Finding that protein in the blood was a much stronger predictor of vascular dementia than Alzheimer’s disease and related dementia.
This opens the possibility that a simple blood test in midlife, one that checks for GDF15, could help doctors flag who is at higher risk of dementia decades down the line. The findings are published in Science Advances.
Israeli research offers new hope for overcoming one of the deadliest brain cancers
The researchers then tested BA-101 together with temozolomide and found that the combination was more effective than either treatment alone. In experiments using mouse models, the combined therapy significantly reduced tumor growth, suggesting that targeting the cancer cells’ resistance mechanism could make existing chemotherapy more powerful.
“Temozolomide resistance remains one of the biggest obstacles in treating glioblastoma,” said Amal. “Our findings suggest that targeting nitrosative stress can restore the tumor’s sensitivity to treatment. While additional studies are needed before this approach can reach patients, these results open an exciting new direction for developing more effective therapies against one of the deadliest cancers.”
The researchers said their findings could point to a new approach in cancer treatment: instead of replacing existing drugs, future therapies could focus on blocking the mechanisms that allow tumors to resist them. If further studies confirm the findings, disabling these survival pathways could allow treatments that have become less effective to regain their ability to attack cancer cells.